Zevra Homepage.
icon news News icon investors Investors icon careers Careers icon contact Contacts
  • About Us dropdown arrow dropdown arrow mobile
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
    • What We Do
    • Partnering
  • Patients & Caregivers dropdown arrow dropdown arrow mobile
    • Clinical Trials
    • Expanded Access Policy
    • Niemann-Pick Disease Type C
    • Urea Cycle Disorders
    • Vascular Ehlers-Danlos
    • Sleep Disorders
  • Our Products
    • MIPLYFFA®
    • OLPRUVA®
    • AZSTARYS®
  • Our Pipeline dropdown arrow dropdown arrow mobile
    • Pipeline
    • Clinical Trials
    • Publications & Presentations
    • Medical Literature
    • Medical Information
    • Investigator-Initiated Studies
  • News
  • Investors
  • Careers
  • Contacts

2021-2020

Home > 2021-2020

Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale

April 4, 2023

Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study

Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment

March 1, 2023

Patterns of Abuse of Prescription Stimulant Products from the National Addictions Vigilance Intervention Program (NAVIPPRO): 2010-2018

January 26, 2023

Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C and WREMB-R as Evaluated in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study

Single-dose Pharmacokinetics of Serdexmethylphenidate/d-Methylphenidate Capsules in Children and Adolescents With ADHD and Healthy Adults: An Evaluation of Age and Body Weight

Steady-State Pharmacokinetics and Relative Bioavailability of Serdexmethylphenidate/d-Methylphenidate, a Treatment for Attention Deficit Hyperactivity Disorder Containing a Novel Prodrug of d-Methylphenidate

Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study

About Us
Our Mission & Vision The Zevra Story Leadership Board of Directors What We Do Partnering
Patients & Caregiver
Clinical Trials Expanded Access Policy Niemann-Pick Disease Type C Urea Cycle Disorders Vascular Ehlers-Danlos Sleep Disorders
Our Products
MIPLYFFA® OLPRUVA® AZSTARYS®
Our Pipeline
Pipeline Clinical Trials Publications & Presentations Medical Literature Medical Information Investigator-Initiated Studies
Careers
Culture Job Openings
Investors
Investor Relations Events & Presentations Stock Quote & Chart Press Releases Corporate Governance SEC Filings Contact Email Alerts
Contact [email protected] 888.958.1253
Zevra Logo
Footer link Zevra Facebook
Footer link Zevra X twitter
Footer link Zevra linkedin
© 2026 Zevra Therapeutics.
All rights reserved.
|
Privacy Policy
|
Notice at Collection
|
Your Privacy Choices
|
Terms of Use